摘要
目的分析口服胸腺肽对CO_(2)激光联合光动力治疗尖锐湿疣复发率的影响,为预防尖锐湿疣治疗后复发提供临床数据参考。方法采用回顾性队列研究方法,收集CO_(2)激光联合光动力治疗尖锐湿疣人群的临床病理资料。根据在光动力治疗期间是否使用口服胸腺肽,分为胸腺肽使用组和未使用胸腺肽组,利用倾向性评分匹配进行1:1匹配,比较匹配前后两组患者光动力治疗后复发情况。结果共收集患者336例,其中胸腺肽使用组171例,未使用胸腺肽组165例。倾向性评分匹配后,两组各纳入120例患者。匹配后,两组病例基线水平差异无统计学意义(P>0.05)。口服胸腺肽组在光动力治疗后半年的复发率为12.50%,未使用胸腺肽组则为14.17%,两组差异无统计学意义(P=0.704)。匹配前,COX回归分析表明,口服胸腺肽对CO_(2)激光联合光动力治疗尖锐湿疣复发率无影响(HR=0.7,95%CI:0.4~1.3,P>0.05)。匹配后,这种关系差异依然无统计学意义(HR=0.9,95%CI:0.4~1.8,P>0.05)。结论口服胸腺肽对CO_(2)激光联合光动力治疗尖锐湿疣复发率无显著影响。
Objective To analyze the effect of oral thymosin on the recurrence rate of condyloma acuminatum(CA)treatd by CO_(2) laser combined with 5-aminolevulinic acid photodynamic therapy(ALA-PDT),and to provide clinical data reference for preventing post-treatment CA recurrence.Methods A retrospective cohort study was conducted on patients with CA treated by CO_(2) laser combined with ALA-PDT,collecting the clinical and pathological data.The patients were divided into thymosin group and non-thymosin group.The propensity score matching was used to compare the recurrence rate of the two groups before and after 1:1 matching.Results A total of 336 patients were included in the study,and 171 patients were in the thymosin group and 165 patients were in the non-thymosin group.After propensity score matching,120 patients were in each group,and there was no significant difference in baseline level between the two groups(P>0.05).The recurrence rate were 12.50%in the thymosin group and 14.17%in the non-thymosin group after half year treatment,with no significant difference(P=0.704).Before matching,multivariate Cox regression analysis showed that oral thymosin had no effect on the recurrence rate of CA after trated with CO_(2) laser combined with ALA-PDT(HR=0.7,95%CI:0.4~1.3,P>0.05).After matching,the correlation was still no statistically significant(HR=0.9,95%CI:0.4~1.8,P>0.05).Conclusion The use of oral thymosin in CO_(2) laser combined with ALA-PDT has no effect on the recurrence rate of CA.
作者
周舒
谷丽
施智男
顾丽群
花卉
周炳荣
ZHOU Shu;GU Li;SHI Zhinan;GU Liqun;HUA Hui;ZHOU Bingrong(Department of Dermatology,Nantong Third Hospital Affiliated to Nantong University,Nantong 226006,China;Department of Dermatology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)
出处
《中国皮肤性病学杂志》
CAS
CSCD
北大核心
2021年第10期1126-1131,共6页
The Chinese Journal of Dermatovenereology
基金
国家自然科学基金(81903246,82073472)
南通市科技计划项目(JC2019024)。